1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Jordan Pharmaceuticals and Healthcare Report Q2 2016

Jordan Pharmaceuticals and Healthcare Report Q2 2016

  • March 2016
  • -
  • Business Monitor International
  • -
  • 89 pages

Includes 3 FREE quarterly updates

BMI View: We uphold our view that Jordan offers a moderately attractive pharmaceutical market formultinational drugmakers, although its potential will remain impeded by the ongoing political andeconomic instabilities within the region. The government remains committed to healthcare modernisationand expansion, and as austerity measures are relaxed, we expect this will help drive medicine uptake andconsumption for the Jordanian population. However, the healthcare system will be strained in light of theincreasing number of refugees entering the country. We expect Jordan's domestic pharmaceutical industryto continue to strengthen as consolidation and merger activity increases in the country - both betweendomestic companies and in partnership with multinationals. Partnership and cooperation should be mostlikely to take the form of licensing and regional representation, with the latter potentially giving Jordan a'production hub' status in the region.

Headline Expenditure Projections

- Pharmaceuticals: JOD683mn (USD962mn) in 2015 to JOD727mn (USD1.02bn) by 2016; +6.4% inlocal currency terms and US dollar terms. Forecast unchanged from Q116.

- Healthcare: JOD1.88bn (USD2.64bn) in 2015 to JOD1.99bn (USD2.80bn) by 2016; +6.21 in localcurrency terms and US dollar terms. Forecast in line with Q116.

Table Of Contents

Jordan Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Jordan 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Jordan 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Jordan 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Jordan 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Jordan 2012-2020) 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Jordan 2012-2020) 18
Patented Drug Market Forecast 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Jordan 2012-2020) 20
Generic Drug Market Forecast 21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Jordan 2012-2020) 22
OTC Medicine Market Forecast 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Jordan 2012-2020) 24
Pharmaceutical Trade Forecast 25
Table: Pharmaceutical Trade Data And Forecasts (Jordan 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Jordan 2014-2020) 27
Industry Risk/Reward Index 28
Middle East and Africa Risk/Reward Index - Q2 2016 28
Jordan Risk/Reward Index 35
Rewards 35
Risks 35
Regulatory Review 38
Intellectual Property Issues 39
Pricing And Reimbursement Regime 41
Market Overview 44
Healthcare Sector 45
Healthcare Insurance 47
Table: Healthcare Resources (Jordan 2010-2015) 50
Table: Healthcare Personnel (Jordan 2010-2015) 50
Table: Healthcare Activity (Jordan 2010-2015) 51
Research and Development 51
Clinical Trials 52
Epidemiology 54
Competitive Landscape 57
Research-Based Industry 57
Table: Multinational Market Activity 59
Generic Drugmakers 60
Pharmaceutical Distribution 60
Pharmaceutical Retail Sector 61
Company Profile 62
Dar al-Dawa 62
Hikma Pharmaceuticals 65
Jordanian Pharmaceutical Manufacturing Company (JPM) 70
Pharma International Company 73
United Pharmaceutical Manufacturers 75
Demographic Forecast 78
Jordan Demographic Forecast 78
Table: Population Headline Indicators (Jordan 1990-2025) 79
Table: Key Population Ratios (Jordan 1990-2025) 79
Table: Urban/Rural Population and Life Expectancy (Jordan 1990-2025) 80
Table: Population By Age Group (Jordan 1990-2025) 80
Table: Population By Age Group % (Jordan 1990-2025) 81
Glossary 83
Methodology 85
Pharmaceutical Expenditure Forecast Model 85
Healthcare Expenditure Forecast Model 85
Notes On Methodology 86
Risk/Reward Index Methodology 87
Index Overview 88
Table: Pharmaceutical Risk/Reward Index Indicators 88
Indicator Weightings 89

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.